Introduction
Human inflammatory bowel diseases (e.g., Crohn disease, ulcerative colitis) are associated with chronic, relapsing inflammation of the intestinal tract of unknown origin (1) . Tissue obtained from patients with inflammatory bowel disease is characterized by a dense leukocyte infiltrate that may play an important role in the pathophysiology of inflammatory tissue injury (2) . This leukocyte accumulation is a cardinal histopathologic feature of acute and chronic inflammatory diseases of the gastrointestinal tract. Leukocyte-endothelial cell interactions that result in recruitment of circulating cells into areas of inflammation are now recognized to represent an early and ratelimiting step in leukocyte-mediated tissue injury (3) . However, this initial adhesive event is followed by another critical step that occurs within the perivascular compartment and has yet to be fully explored. Emigrated and residing cells must migrate along a chemotactic signal toward the site of infection/injury, identify the offending antigen, and undergo activation to perform their respective cell-specific functions.
Members of the integrin family of molecules mediate cell adhesion to ECM proteins such as collagen, fibronectin, and laminin (4) . Recent studies suggest that interactions between leukocyte-associated integrins and the interstitial matrix may promote the migration and/or activation of extravasated leukocytes (e.g., T cells and monocytes) within the perivascular compartment (5, 6) . The ECM-rich environment of perivascular tissue is thought to be an important site where certain human leukocytes undergo differentiation (e.g., monocytes) and activation (neutrophils, monocytes, lymphocytes) upon extravascular migration (7) . The α 1 β 1 integrin is a major cell surface receptor for collagens with a preference for type IV collagen (8) . Expression of α 1 β 1 in the adult is largely confined to mesenchymal cells, notably smooth muscle cells, fibroblasts, stellate cells, hepatocytes, and microvascular endothelium (9) (10) (11) (12) . While little detectable α 1 β 1 is expressed on resting leukocytes, α 1 β 1 expression is induced on the surface of T lymphocytes and monocytes upon activation (4, 13) . Expression of α 1 β 1 has also been demonstrated on tissue-infiltrating T cells from a variety of chronic inflammatory settings, including the synovium of rheumatoid arthritis patients, lung tissue of sarcoidosis patients, and atherosclerotic plaques (4, 14) . The importance of α 1 β 1 interaction with the ECM-rich environment of peripheral tissue was recently demonstrated in several in vivo models of inflammation outside the gut (e.g., hypersensitivity and arthritis) (5, 15) .
The presumed role of the ECM environment in the inflammatory process, and the fact that chronically activated immune cells can express this integrin, led us to the hypothesis that α 1 β 1 integrin may contribute to the pathophysiology of intestinal inflammation. Therefore we wanted to assess whether α 1 β 1 -mediated interactions, which occur in the perivascular compartment independently of the adhesive interactions responsible for leukocyte recruitment at the endothelium, contribute to the pathophysiology of mucosal injury and inflammation in the dextran sodium sulfate (DSS) mouse model of colitis.
In this report, we found that treatment of DSSexposed wild-type (WT) mice with a blocking anti-α 1 mAb resulted in significant attenuation of colitis, and that similar protection was conferred to DSS-exposed mice lacking α 1 β 1 integrin. Blockade of α 1 β 1 was also associated with decreased mucosal inflammatory cell infiltrate and cytokine production. Importantly, we demonstrated that both induction of DSS-induced colitis and α 1 -mediated inhibition of colitis occurred independently of lymphocytes, and identified the monocyte as a key α 1 β 1 -expressing cell type involved in the development of colitis in this model. Given that α 1 β 1 represents a main collagen-binding integrin expressed on leukocytes, our study highlights the important role ECM-leukocyte interactions play in the pathogenesis of colitis, with particular relevance to monocytes.
Methods
Mice. Six-to eight-week-old male BALB/c and recombinase-activating gene-2 knockout mice [Rag2 -/-mice; C.129(B6)-Rag2 tml N12] were purchased from Taconic Farms (Germantown, New York, USA). α 1 integrin knockout mice (α 1 -/-) on a BALB/c background were obtained as previously described (16) .
Induction of colitis. Mice were fed 5% (wt/vol) DSS (molecular weight, 40 kDa; ICN Biomedicals Inc., Aurora, Ohio, USA) dissolved in water that was filtered using water purification systems from Millipore Corp. (Bedford, Massachusetts, USA) for 7 days (17) . No mortality was observed during the 7 days of DSS administration.
mAb's. Function-blocking mAb against murine α 1 integrin chain Ha31/8 (hamster anti-α 1 ) (18) and the hamster isotope control mAb Ha4/8 (hamster anti-KLH) (18) were prepared in an azide-free and lowendotoxin format. Two hundred micrograms of mAb was administered intraperitoneally 12 hours prior to induction of DSS-colitis; this dose was repeated every 48 hours for the duration of the experiment. For immunohistochemistry, Ha31/8 and Ha4/8 mAb's were fluorescently labeled using the Alexa 488 protein labeling kit as recommended (Molecular Probes Inc., Eugene, Oregon, USA). FITC-and phycoerythrin-conjugated (PE-conjugated) mAb's 145-2C11 (hamster anti-CD3e), M1/70 (rat anti-CD11b), rmC5-3 (rat anti-CD14), and RB6-8C5 (rat anti-Ly-6G/Gr-1) were from Pharmingen (San Diego, California, USA); PE-conjugated CI:A3-1 (rat anti-F4/80) was from Serotec Ltd. (Kidlington, United Kingdom).
Assessment of inflammation in DSS-treated mice. Daily clinical assessment of DSS-treated animals included measurement of drinking volume and body weight, evaluation of stool consistency, and the presence of blood in the stools by a guaiac paper test (ColoScreen; Helena Laboratories Corp., Beaumont, Texas, USA). A validated clinical disease activity index (19) ranging from 0 to 4 was calculated using the following parameters: stool consistency, presence or absence of fecal blood, and weight loss. Mice were sacrificed at day 7 and the colons were removed; length and weight were measured after exclusion of the cecum and prior to division for histology, myeloperoxidase activity, and RNA extraction.
Histology. Histology was performed on three samples of distal colon for each animal. Samples were fixed in Zamboni solution prior to embedding in JB-4 (Polysciences Inc., Warrington, Pennsylvania, USA) and staining with hematoxylin and eosin. All histologic quantitation was performed in a blinded fashion using a validated scoring system (20) . Three independent parameters were measured: severity of inflammation (0-3: none, slight, moderate, severe); depth of injury (0-3: none, mucosal, mucosal and submucosal, transmural); and crypt damage (0-4: none, basal one-third damaged, basal two-thirds damaged, only surface epithelium intact, entire crypt and epithelium lost). The score of each parameter was multiplied by a factor reflecting the percentage of tissue involvement (×1: 0-25%, ×2: 26-50%, ×3: 51-75%, ×4: 76-100%) and these values were summed to obtain the histology score (maximum possible score, 40). In addition, the percentage of ulcerated mucosal surface was measured by computer-aided morphometric analysis (MetaMorph; Universal Imaging Corp., West Chester, Pennsylvania, USA). Images of three cross sections of the distal colonic wall were captured via an ECLIPSE E600 upright light microscope (Nikon Inc., Melville, New York, USA) coupled to a SenSys CCD camera system (Roper Scientific Inc., Trenton, New Jersey, USA). The ulcerated mucosal surface was defined by loss of mucosal epithelium and expressed as percentage of the total luminal perimeter for each section.
For immunohistochemical staining, freshly isolated colonic tissue from the distal portion of the colon was frozen in dry ice using OCT compound (Sakura Finetek, Torrance, California, USA). Acetone-fixed frozen sections (10-µm thick) were blocked in a 3% BSA/PBS solution for 30 minutes at room temperature. Slides were washed and sections were incubated with 5 µg/ml of Alexa 488-labeled anti-α 1 mAb in 3% BSA/PBS for 1 hour at room temperature. Slides were then washed in PBS and mounted in Citifluor (Ted Pella Inc., Redding, California, USA). Dual-color immunohistochemistry was performed with the inclusion of PE-conjugated mAb during the primary staining step. The stained sections were examined by dual immunofluorescent microscopy (Leica Microsystems AG, Wetzlar, Germany).
The number and activation state of monocytes/ macrophages infiltrating the lamina propria was quantitated by dual-color immunohistochemical analysis using FITC-conjugated anti-CD14 and PE-conjugated anti-F4/80 mAb's. The numbers of F4/80 + and F4/80 + CD14 + cells per high-power field (hpf) observed following different treatment regimens were counted by two independent observers. A total of eight randomly selected hpf's per animal were counted, with five animals analyzed per group.
Tissue myeloperoxidase activity. Samples of mid-to-distal colon (adjacent to tissue used for histology) were obtained from either control or DSS-treated animals, rinsed with cold PBS, blotted dry, and immediately frozen in liquid nitrogen. The samples were stored at -80°C until being thawed for myeloperoxidase activity determination using the O-dianisidine method previously described (21) . Myeloperoxidase activity was expressed as the amount of enzyme necessary to produce a change in absorbance of 1.0 per minute per gram wet weight of tissue.
RNA extraction. Segments from the distal colon (five per group) were snap frozen and stored at -80°C. Total cellular RNA was isolated by homogenizing tissue in TRIzol (Gibco BRL, Life Technologies, Paisley, United Kingdom). RNA was then chloroform-extracted and isopropanol was precipitated. The yield and purity of RNA was determined by spectroscopic analysis; RNA was stored at -80°C until use.
RNase protection assay. Cytokine mRNA levels were analyzed by RNase protection assay using the RiboQuant multiprobe set (Pharmingen) as described (22) . In brief, RNA obtained from distal colons was hybridized overnight to the 32 P-labeled RNA probe from a customized mouse template set (Pharmingen). Protected RNA was analyzed on a 6% denaturing polyacrylamide gel and quantitated using a PhosphorImager (Storm 860) and ImageQuant 5.0 software (both from Molecular Dynamics, Sunnyvale, California, USA). Cytokine values were expressed as fold increase over the mean values for healthy control colon tissue corrected for the housekeeping gene GAPDH for each condition/gel lane.
Data analysis. Statistical analyses were performed using one-way ANOVA with Scheffé's post hoc test or the Kruskal-Wallis test when appropriate. Two-way ANOVA for repeated measures was used to test for group and time effects on the clinical data (e.g., disease activity index) over the 7 successive days of clinical observation. A P value below 0.05 was considered significant.
Results
Anti-α 1 integrin mAb protects from colitis associated with DSS administration. To evaluate the role of α 1 β 1 in DSS-mediated colitis (17) , anti-α 1 or control mAb administration was initiated 12 hours prior to DSS exposure in the drinking water (for 7 days) of WT mice; mAb administration was repeated every 48 hours thereafter for the duration of the study. DSS administration in isotype control mAb-treated WT mice was associated with significant clinical changes, including weight loss (starting on day 2), the appearance of occult fecal blood (on day 3), and diarrhea (on day 4) (Figure 1 ). In contrast, anti-α 1 mAb administration resulted in a significant amelioration in the severity of DSS-colitis by day 7, as shown by a 71% reduction in the clinical disease activity index ( Figure 1 ). The improvement in disease parameters characteristically associated with DSS-induced inflammation such as colon shortening and colon weight gain confirmed the observed protection (Table 1 ).
Figure 1
Treatment with anti-α 1 mAb prevents DSS-mediated colitis. Mice were fed DSS over 7 days and treated with mAb (control or anti-α 1 ) every second day starting at day 0. Disease severity was measured daily and is expressed in terms of (a) body weight, (b) fecal blood, (c) diarrhea, and (d) disease activity index (combined index of a + b + c). The isotype mAb-treated group exhibited no significant differences from WT mice receiving DSS alone (see Figure 2 ). *P < 0.05; anti-α 1 mAb vs. isotype mAb. Data represent mean ± SEM. Computerized morphometry quantified and confirmed that the degree of mucosal injury and ulceration caused by DSS was significantly reduced in the anti-α 1 mAb-treated mice (Table 2) . Consistent with the dramatic effects anti-α 1 mAb treatment had on reducing the cellular infiltrate associated with DSS-induced colitis, neutrophil accumulation, as measured by colonic myeloperoxidase activity, was reduced by more than 75% in DSS-treated mice receiving anti-α 1 mAb (Table 2 ).
Mice lacking α 1 β 1 integrin are similarly protected against DSS-induced colitis. While the anti-α 1 mAb used has been shown to be a highly specific function-blocking inhibitor of murine α 1 (5), we wanted to confirm in an mAb-independent manner the importance of α 1 β 1 in the DSS colitis model. The DSS colitis model was examined in mice that were deficient in the α 1 subunit of α 1 β 1 integrin. Consistent with the degree of inhibition seen with anti-α 1 mAb, the severity of DSSinduced colitis was significantly reduced (62% inhibition) in α 1 integrin-deficient mice (Figure 3 ). Other disease-associated parameters such as colon shortening and colon weight gain were reduced in the α 1 -deficient mice compared with WT mice; the degree of reduction in the α 1 -deficient mice was comparable to that seen in WT mice treated with anti-α 1 mAb ( Table  1 ). The improvement achieved by genetic disruption of α 1 was confirmed histologically. Colons from DSStreated α 1 -deficient mice showed decreased leukocyte infiltration and were protected from mucosal injury ( Figure 4) . The decreased ulceration, mucosal injury, and neutrophil infiltration seen in the DSS-treated α 1 -deficient mice was comparable to that seen with anti-α 1 mAb treatment ( Table 2) .
Blockade of α 1 β 1 results in decreased inflammatory cytokine mRNA expression in WT mice. Since certain cytokines (such as TNF-α) also contribute to disease progression and tissue damage in human inflammatory bowel disease, we were interested in whether the α 1 -mediated protection observed in murine DSS colitis was reflected by changes in mRNA expression of Th1 and Th2 cytokines thought to be important in ulcerative colitis. Administration of DSS to WT mice led to significant upregulation of TNF-α, IFN-γ, IL-1β, IL-12, and IL-10 mRNA expression Table 1, and Table 2 ). Isotype control Ig-treated Rag2 -/-mice responded to DSS administration with even more severe colitis than was seen in WT mice with DSScolitis. Interestingly, when T cells and B cells were absent, the protective effect of anti-α 1 mAb was maintained, suggesting that the inhibitory effect of α 1 blockade is independent of lymphocytes and is most likely mediated by cells of the innate immune system. Colons of Rag2 -/-mice exposed to DSS and treated with either control or anti-α 1 mAb were also analyzed for induction of inflammatory cytokines ( Figure 7) . Exposure of Rag2 -/-mice to DSS resulted in similar fold induction of TNF-α, IFN-γ, and IL-1β to that seen in WT mice. In contrast to DSS-exposed WT mice and consistent with their immunodeficient status, Rag2 -/-mice showed decreased induction of IL-12 and no induction of IL-10 in response to DSS. Unlike what was seen in WT mice, anti-α 1 mAb treatment of DSS-exposed Rag2 -/-mice resulted in little change in inflammatory cytokine production, with the exception of TNF-α, for which a small but significant reduction was seen (Figure 7) .
Expression of α 1 β 1 on lamina propriainfiltrating leukocytes and its effect on monocyte recruitment and activation. Given the fact that α 1 β 1 is a prominent leukocyteassociated collagen-binding integrin, α 1 β 1 may enhance intestinal inflammation by promoting migration and/or activation of extravasated leukocytes within the tissue interstitium. Since α 1 β 1 integrin can be expressed on both activated T lymphocytes and monocytes (4, 5, 13), dual-color immunohistochemistry was performed on colons from DSS-treated mice to determine the nature of the infiltrating cells and whether they express α 1 β 1 integrin (Figure 8 ). Colons were examined for α 1 β 1 expression and cell lineage markers. Consistent with previous reports (9), α 1 β 1 was highly expressed on smooth muscle cells within the colon. Colons from mice given normal drinking water showed very few infiltrating T cells (CD3 + ) or granulocytes/monocytes (CD11b + ) 
Discussion
In this report, we used a well-established model of colitis associated with administration of DSS to demonstrate the functional importance of α 1 β 1 integrin in the pathogenesis of this disease. Furthermore, we have identified the monocyte as a key α 1 β 1 -expressing cell type involved in the development of colitis in this model. Given that α 1 β 1 represents a main collagenbinding integrin expressed on leukocytes, our study highlights the important role ECM-leukocyte interactions play in the pathogenesis of colitis, with particular relevance to monocytes.
DSS is a sulfated polymer that is thought to induce mucosal injury and inflammation initially through a direct toxic effect on epithelial cells with subsequent recruitment and activation of macrophages and T cells, resulting in upregulation of both Th1 and Th2 cytokines and other inflammatory mediators, and thus leading to the development of severe colitis (20) . DSS-induced colitis was originally viewed as a T cell-independent model because it is observed in severe combined immunodeficient (SCID) mice lacking both T and B lymphocytes (25) . However, recent reports demonstrating that DSS-colitis is more severe in T cell-and B cell-deficient mice suggest that regulatory T cells may be critical in later phases of disease (26) . These findings are consistent with our data showing that DSS-colitis is more severe in Rag2 -/-mice and support the hypothesis that subsets of T cells are important for limiting the severity of DSS-colitis (2) .
We found that DSS-exposed WT mice receiving anti-α 1 mAb had significant attenuation of colitis, suggesting that α 1 β 1 integrin is involved in mechanisms that
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The regulate the initiation and/or progression of inflammation in this model of colitis. Genetic deletion of α 1 resulted in a similar degree of protection from DSS-induced inflammation compared with anti-α 1 mAb treatment in WT mice, confirming the importance of α 1 β 1 integrin in gut inflammation. Protection from DSS-associated disease can also be achieved by blockade with anti-α 1 mAb in Rag2 -/-mice despite the lack of mature T and B cells, suggesting that α 1 antagonism can modulate inflammation by acting on other cell populations. The DSS colitis model is thought to have a strong neutrophil/ monocyte-based component in the acute phase of inflammation (17) . Our immunohistologic analysis of the infiltrating cells in DSS-colitis revealed that while both neutrophils and monocytes were present, α 1 β 1 expression was restricted to the monocyte population. These findings agree with previous reports demonstrating that monocytes rapidly upregulate expression of α 1 β 1 upon activation (13) , and that α 1 β 1 is expressed on monocytes at sites of inflammation (5) .
Although the pathogenesis of DSS-mediated colitis is incompletely understood, the recruitment and activation of macrophages within the intestinal mucosa seems to have a critical role (27) . The importance of monocytes and ECM in the inflammatory cascade is underscored by recently published gene expression data demonstrating that integrin-mediated attachment of monocytes to ECM resulted in increased expression of numerous inflammatory and immune response genes important in promoting cell recruitment and activation (6) . Antagonism of α 1 β 1 -mediated interaction with collagen may serve to inhibit monocyte movement and/or activation within the inflamed interstitium, resulting in an attenuated inflammatory response. Consistent with both hypotheses, blockade of α 1 β 1 by mAb or knockout resulted in a sharp reduction in the number and activation status of lamina propria-infiltrating monocytes/macrophages seen in response to DSS.
In general, disruption of adhesive interactions can affect leukocyte recruitment by affecting entry into tissues (endothelial/leukocyte interactions) or by affecting migration of cells within the inflamed tissue. In the case of α 1 β 1 , disruption of endothelial/leukocyte adhesion as a possible mechanism of action can be excluded because α 1 β 1 ligands (collagen, laminin) are not expressed on the surface of endothelial cells. Direct involvement of α 1 β 1 in endothelium-dependent leukocyte adhesion was also ruled out experimentally in a pilot intravital microscopy study that showed no effect of either α 1 blockade or deletion on endothelium-dependent leukocyte recruitment (data not shown). In vitro studies clearly indicate that α 1 β 1 is important in regulating cell movement as this integrin has been shown to be critically involved in controlling cell migration on collagen matrices (16, 28) . The potential involvement of α 1 β 1 in regulating in vivo cell migration within ECMrich tissues represents a possible mechanism of action requiring further study.
While engagement of α 1 β 1 may be important in allowing migration of leukocytes to inflammatory sites, it is also capable of promoting cellular activation. For instance, integrin-mediated binding to collagen provides a costimulatory signal for T cell activation, resulting in increased proliferation and secretion of proinflammatory cytokines such as TNF-α and IFN-γ (29) (30) (31) . The proinflammatory roles of IFN-γ and TNF-α in the activation of macrophages in animal models of colitis and in human inflammatory bowel disease have been well established (32, 33) . Both these cytokines have also been shown to be important in the pathology of DSS-induced colitis. For instance, the
Figure 6
Development and α 1 -mediated inhibition of DSS-induced colitis is independent of lymphocytes. Immunodeficient Rag2 -/-mice were fed DSS over 7 days and treated with mAb (control or anti-α 1 ) every second day starting at day 0. Disease severity was measured daily and is expressed in terms of (a) body weight, (b) fecal blood, (c) diarrhea, and (d) disease activity index (combined index of a + b + c). The isotype mAb-treated group exhibited an exaggerated course and severity of colitis compared with WT mice receiving either DSS alone or with the isotype-matched mAb (compare with Figure 1 and Figure 2 ). *P < 0.05, anti-α 1 mAb vs. isotype mAb. Data represent mean ± SEM. severity of DSS-colitis was significantly attenuated in mice given anti-IFN-γ and/or anti-TNF-α mAb's (34) . Antagonism of α 1 β 1 in WT mice resulted in dramatic reductions in the levels of proinflammatory cytokines induced by DSS, including both TNF-α and IFN-γ. The decreased cytokine expression caused by α 1 β 1 blockade was not skewed toward Th1-or Th2-type cytokines, as levels of both Th1 (IFN-γ, IL-1α, TNF-α) and Th2 (IL-10) cytokines were similarly reduced. Consistent with a role for α 1 β 1 in regulating monocyte/ macrophage activation is the fact that both α 1 deficiency and anti-α 1 mAb treatment significantly reduced the activation status of lamina propria-infiltrating monocytes/macrophages as judged by coexpression of the CD14 activation marker. Whether the impaired monocyte/macro-phage activation that is seen in WT mice upon α 1 β 1 blockade is due solely to blockade of proinflammatory cytokines is unknown. Inhibition of α 1 β 1 can potentially also have other antiinflammatory effects, as evidenced by the ability of anti-α 1 mAb treatment to improve disease in Rag2 -/-mice while having minimal impact on expression of the proinflammatory cytokines studied. Clearly, the mechanistic and cellular pathways responsible for cytokine production in Rag2 -/-mice in response to DSS are different from what is seen in the presence of an intact immune system. This is perhaps not surprising given their immunocompromised status, and is also borne out by the altered pattern of cytokines induced by DSS in WT and Rag2 -/-mice.
It is not clear whether the inhibition of leukocyte infiltration in the inflamed colons that is observed
Figure 7
Inflammatory cytokine mRNA expression in response to DSS is altered in Rag2 -/--immunodeficient mice compared with WT mice and is largely uninhibited by anti-α 1 mAb treatment. Levels of TNF-α, IFN-γ, IL-1β, IL-12, and IL-10 mRNA expression were measured in colons from Rag2 -/-mice exposed for 7 days to DSS and treated with either isotype control mAb or anti-α 1 mAb. For quantitation and to allow comparison with Figure 5 , cytokine values are expressed as fold increase over the mean values obtained for healthy control colon tissue from WT mice. *P < 0.05, anti-α 1 mAb vs. isotype mAb; # P < 0.05 vs. Rag2 -/-+ H 2 O. Data represent mean ± SEM. ctrl, control.
Figure 8
DSS-induced colitis results in accumulation of granulocytes/monocytes that is significantly inhibited by treatment with anti-α 1 mAb. Immunohistochemical staining of colonic cross sections from WT mice receiving either regular water (a and e) or mice that were treated for 7 days with DSS in the absence (b, d, f, and h) or presence (c and g) of anti-α 1 mAb. Dual immunofluorescent staining of colon tissue was performed with Alexa 488-conjugated anti-α 1 mAb and either PE-conjugated anti-CD3 mAb (a-d) or anti-CD11b mAb (e-h). PE-conjugated mAb's were specific for granulocytes/monocytes (anti-CD11b) and T lymphocytes (anti-CD3). No staining was seen with Alexa 488-and PE-conjugated isotype control mAb's (not shown). In a-c and e-g, magnification is ×100 and bar represents 100 µm. In d and h, magnification is ×400 and bar represents 25 µm.
with anti-α 1 mAb treatment or α 1 deficiency represents a direct inhibitory effect on cell migration or is a consequence of disruption of a cellular activation event that then leads to decreased leukocyte recruitment. While α 1 blockade may directly affect both cell migration and activation, α 1 antagonism can clearly also act indirectly to decrease inflammation. For example, in response to DSS, colonic recruitment of both monocytes and neutrophils is significantly reduced by α 1 blockade, yet only monocytes were found to express α 1 β 1 . Thus, while the monocyte represents a key cell type that α 1 antagonism is acting upon in the DSS-colitis model, the reduction in neutrophil recruitment is likely a secondary effect of inhibiting monocyte recruitment and activation.
Anti-adhesive therapies for inflammatory bowel diseases have traditionally focused on preventing leukocyte recruitment to inflammatory sites by interfering with leukocyte-endothelial interactions. Development of DSS-colitis can be reduced through blockade of either α 4 β 1 /VCAM-1 (35) or α L β 2 /ICAM-1 interactions (36, 37) , and in humans, an anti-α 4 mAb shows much promise in treating Crohn disease (38) . Our study expands the role of adhesion molecules in inflammatory bowel disease beyond recruitment of circulating cells at the endothelial surface, and supports an emerging paradigm shift highlighting the importance of adhesion molecules within the ECMrich environment of peripheral tissue (29) .
The finding that emigrated leukocytes at sites of inflammation can express α 1 β 1 , a main collagen receptor, on their surface suggests that expression of this integrin is physically and temporally situated to play an important role in the inflammatory cascade. The importance of α 1 β 1 in the inflammatory process is underscored by the strong protective effects that both mAb-based inhibition and genetic deletion of this integrin have in the DSS model of colitis. A similar protective effect of anti-α 1 mAb and α 1 deficiency was previously seen in animal models of hypersensitivity and arthritis (5, 15) . Our study not only reinforces the importance of peripheral tissues to the inflammatory disease process by extending it to include inflammatory bowel disease, but also specifically highlights the monocyte as an important α 1 β 1 -expressing cell type in the pathogenesis of colitis. We demonstrated that development and α 1 -mediated inhibition of DSS-induced colitis was independent of lymphocytes, and that in this model, activated monocytes represent the main α 1 β 1 -expressing cell type seen within the inflammatory infiltrate. The ability of α 1 blockade to prevent monocyte accumulation, activation, and proinflammatory cytokine production within the inflamed colon is particularly important, given that activated monocytes and their production of proinflammatory cytokines has been linked to the pathogenesis of inflammatory bowel disease in humans (33) . In summary, we have demonstrated the importance of the ECM-rich peripheral tissue environment in modulating immune responses, and propose that therapies targeting monocyte interaction with ECM may represent a powerful new approach in the treatment of patients with inflammatory bowel disease.
